Medifast (NYSE:MED) Updates FY 2026 Earnings Guidance

Medifast (NYSE:MED) updated its FY 2026 earnings guidance on Monday. The company provided earnings per share guidance of -2.750–1.550 for the period, compared to the consensus earnings per share estimate of -1.980. The company issued revenue guidance of $270.0 million-$300.0 million, compared to the consensus revenue estimate of $275.3 million. Medifast also updated its Q2 2026 guidance to -1.000–0.500 EPS.

Wall Street Analyst Weigh In

MED has been the topic of a number of recent analyst reports. Stephens lowered their target price on shares of Medifast from $15.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, February 19th. Wall Street Zen upgraded shares of Medifast from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Medifast in a research report on Thursday, January 22nd. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and an average target price of $12.00.

Medifast Price Performance

NYSE MED traded down $0.33 during trading hours on Monday, reaching $10.58. 150,459 shares of the stock traded hands, compared to its average volume of 241,677. The stock has a 50 day simple moving average of $10.41 and a two-hundred day simple moving average of $11.10. Medifast has a 1 year low of $9.22 and a 1 year high of $15.46. The company has a market cap of $116.76 million, a price-to-earnings ratio of -6.19 and a beta of 0.55.

Medifast (NYSE:MED) last released its quarterly earnings results on Monday, May 4th. The specialty retailer reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.36. Medifast had a negative return on equity of 4.27% and a negative net margin of 4.84%.The business had revenue of $76.04 million for the quarter, compared to the consensus estimate of $69.20 million. Medifast has set its FY 2026 guidance at -2.750–1.550 EPS and its Q2 2026 guidance at -1.000–0.500 EPS. On average, sell-side analysts forecast that Medifast will post -2 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Daniel R. Chard purchased 17,678 shares of the stock in a transaction on Friday, March 20th. The shares were acquired at an average price of $10.11 per share, for a total transaction of $178,724.58. Following the completion of the transaction, the chief executive officer directly owned 17,678 shares of the company’s stock, valued at approximately $178,724.58. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 3.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Medifast

A number of large investors have recently added to or reduced their stakes in the company. Corient Private Wealth LLC purchased a new stake in Medifast during the fourth quarter valued at about $139,000. Empowered Funds LLC increased its holdings in shares of Medifast by 11.1% in the fourth quarter. Empowered Funds LLC now owns 44,773 shares of the specialty retailer’s stock worth $478,000 after buying an additional 4,462 shares during the period. Man Group plc increased its holdings in shares of Medifast by 10.8% in the fourth quarter. Man Group plc now owns 236,500 shares of the specialty retailer’s stock worth $2,526,000 after buying an additional 23,070 shares during the period. Trexquant Investment LP increased its holdings in shares of Medifast by 88.0% in the fourth quarter. Trexquant Investment LP now owns 126,959 shares of the specialty retailer’s stock worth $1,356,000 after buying an additional 59,439 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Medifast by 24.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 22,905 shares of the specialty retailer’s stock worth $245,000 after buying an additional 4,500 shares during the period. Hedge funds and other institutional investors own 95.51% of the company’s stock.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.